US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Antibody Technologies: market research reports

Monoclonal antibodies (mAbs) are large protein molecules produced by white blood cells that seek out and destroy harmful foreign substances. Monoclonal antibodies are finding wide application in many areas of medicine and biologic science. These antibodies have begun to replace conventional antibodies in blood banking and are used in the identification of organisms in the bacteriology laboratory.
Monoclonal antibodies have also been extensively used in radioimmunoassay to measure serum levels of various substances. They have very useful in quantitating types of WBCs and subgroups of lymphocytes. They are also used in the diagnosis of leukemia. More recently, monoclonal antibodies have been used in the treatment of malignancies. They have been used to treat transplant rejection episodes, purge bone marrow of tumor cells in bone marrow transplants, and remove mature T cells that cause GVH disease in bone marrow transplants.

There are several types of monoclonal antibodies on the market and in development. Most of the monoclonal antibodies on the market are whole antibodies, while some are fragments of antibodies. There are also variable fragment monoclonal antibodies and bispecific monoclonal antibodies.

RSS Feeds

Antibody Technologies market research reports and industry analysis

< prev 1    3  4  5  6  7  8  9  10  
Monoclonal Antibodies Partnering Terms and Agreements
8/1/2014 | published by: Current Partnering
... obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest ...  |  read more...
USD 2,995
Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024
8/4/2014 | published by: Roots Analysis
... more than USD 600 million in 2014. 2. About 45 molecules are currently in clinical development. Of these, approximately 25% are in Phase II or Phase III of development. As expected, the preclinical pipeline is ...  |  read more...
USD 1,899
Western Blotting Market by Product (Instruments (Manual/Semi-automated/Automated), Consumables (Kits/Reagents/Membrane), by Application (Disease Diagnosis/Agriculture/Biomedical Research) - End-User Analysis & Global Forecast to 2018
8/4/2014 | published by: MarketsandMarkets
... has witnessed various technological advancements to improve the sensitivity, reproducibility, quantifiability, and speed of western blot experiments. These advancements have led to a growth in the number of applications. Western blotting instruments and consumables have ...  |  read more...
USD 4,650
Antibody Deals and Alliances of 2013
8/1/2014 | published by: Current Partnering
... during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. ...  |  read more...
USD 1,495
Cancer Monoclonal Antibody Partnering Terms and Agreements
8/1/2014 | published by: Current Partnering
... healthcare companies. Trends in cancer monoclonal antibody partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer monoclonal antibody partnering contract documents Top cancer monoclonal antibody deals by value The Cancer Monoclonal ...  |  read more...
USD 1,995
Antibodies in Oncology: Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of more than 107 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 264 drug targets that are included ...  |  read more...
USD 6,746
Antibodies in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... for the second wave in the lucrative field of therapeutic antibodies. There are today 315 companies plus partners developing 701 antibody drugs in 1690 developmental projects in cancer. In addition, there are 8 suspended drugs ...  |  read more...
USD 6,746
The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition
9/22/2013 | published by: Kalorama Information
... designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the ...  |  read more...
USD 2,995
Single-use Bioreactors Market, 2014-2024
4/23/2014 | published by: Roots Analysis
... the use of vials and pipettes, has emerged rapidly over the last decade. Today, this term surrounds a wide range of primarily plastic disposable technologies that are suitable for a wide variety of scales, from ...  |  read more...
USD 1,899
Drug Delivery Technologies Market Forecast 2014-2024
4/30/2014 | published by: Visiongain
... this market and related technologies? Visiongain’s new report shows you potential revenues and other trends to 2024, discussing data, opportunities and prospects. Our 202 page report provides 157 tables, charts, and graphs. Discover the most ...  |  read more...
USD 3,004
Conference Documentation: ADC Summit 2014
5/19/2014 | published by: SMI Publishing, Ltd
... Group is proud to announce that the ADC Summit 2013 conference will be returning to London in 2014. If you are interested in getting involved, please contact Dale Butler on 020 7827 6044 or via email  |  read more...
USD 788.78
Analytical Tool - Apoptosis in Oncology
3/25/2014 | published by: BioSeeker Group AB
... of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product ...  |  read more...
USD 11,625
Analytical Tool - Antibodies and Peptides in Oncology
3/25/2014 | published by: BioSeeker Group AB
... business development in the antibody and peptide cancer drug competitive landscape. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide ...  |  read more...
USD 22,312.50
Chronic Lymphocytic Leukaemia: KOL Insight
5/27/2014 | published by: FirstWord
... radically altering the treatment algorithm. From Roche’s improved anti-CD20 monoclonal antibody Gazyva, to Pharmacyclics/Janssen Biotech’s Imbruvica, the treatment landscape is being transformed. Drivers of change Targeted therapies. Most significantly, KOLs predict that therapies from Roche, ...  |  read more...
USD 4,995
Antibody Partnering Terms and Agreements
6/1/2014 | published by: Current Partnering
... leading companies worldwide. Antibody Partnering Terms and Agreements includes: Trends in antibody dealmaking in the biopharma industry since 2009 Analysis of antibody deal structure Access to headline, upfront, milestone and royalty data Case studies of ...  |  read more...
USD 2,995
Analytical Tool - Cancer Immunotherapy
3/25/2014 | published by: BioSeeker Group AB
... is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays ...  |  read more...
USD 20,437.50
Analytical Tool - Cancer Therapeutic Antibodies
3/25/2014 | published by: BioSeeker Group AB
... of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product ...  |  read more...
USD 14,810
Bispecific Antibody Therapeutics Market, 2013-2023
9/24/2013 | published by: Roots Analysis
... anti-CD3 antibody, Orthoclone Okt3, in 1986. A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together ...  |  read more...
USD 1,699
EMERGENCE OF BIOGENERICS ERA IN JAPAN - IT'S TIME TO WELCOME ANTIBODY BIOSIMILARS OF FOREIGN ORIGINS SOON
2/21/2014 | published by: MP Advisors
... of biosimilars with first ‘mab’ approval expected in 2014. This approval (Remicade- FY03/13A sales ¥73.5, infiximab from Nippon Kayaku by YE 14) will be marked as a milestone development because – 1.) it will open ...  |  read more...
USD 2,500
Competitor Analysis: Immunocytokines
1/3/2014 | published by: La Merie Publishing
... work with engineering of the cytokine payloads promises new molecular entities with better tolerability and safety. The present Competitive Intelligence report about  Immunocytokines provides a competitor evaluation in the field of recombinant fusion proteins of ...  |  read more...
USD 334
Cancer Monoclonal Antibody Partnering Terms and Agreements
10/1/2013 | published by: Current Partnering
... healthcare companies. Trends in cancer monoclonal antibody partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer monoclonal antibody partnering contract documents Top cancer monoclonal antibody deals by value The Cancer Monoclonal ...  |  read more...
USD 1,795
Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors
2/28/2014 | published by: La Merie Publishing
... in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of March 2014. Purchase of the downloadable pdf report includes a ...  |  read more...
USD 555
Competitor Analysis: EGF-R Antibodies –Biosimilars and Biosuperiors
3/4/2014 | published by: La Merie Publishing
... to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access ...  |  read more...
USD 347
The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
10/16/2013 | published by: La Merie Publishing
... have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are ...  |  read more...
USD 1,919
Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth
12/15/2013 | published by: GBI Research
... Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic ...  |  read more...
USD 3,500
< prev 1    3  4  5  6  7  8  9  10